Saroja Pharma Industries India Limited (SAROJA)
📢 Recent Corporate Announcements
Saroja Pharma Industries India Limited has announced the appointment of Mr. Ravindra Shivaji Salaskar as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective September 25, 2026. Mr. Salaskar, who is 65 years old and has over 40 years of experience in finance and accounts, currently serves as a Whole-time Director with a term ending October 8, 2030. He will hold the CFO role alongside his directorship. The announcement reflects an internal reassignment of the top finance position.
- Appointment of Mr. Ravindra Shivaji Salaskar as CFO effective September 25, 2026
- Appointee brings over 40 years of experience in finance, accounts, and compliance
- Continues as Whole-time Director under existing 5-year term through October 8, 2030
- Board meeting commenced at 12:00 p.m. and concluded at 01:30 p.m. on September 25, 2026
Saroja Pharma Industries India Limited has issued the notice for its 8th Annual General Meeting scheduled for September 30, 2026, via Video Conferencing. Key agenda items include adopting the FY2025-26 audited financial statements and regularizing board appointments. Shareholders will vote on re-designating Mr. Pulinattu Damodaran Nandakumar as a Whole-time Director without remuneration for 5 years, and appointing Mr. Ravindra Shivaji Salaskar as Whole-time Director for 5 years. Remote e-voting runs from September 26 to September 29, 2026, with the cut-off date fixed as September 23, 2026.
- 8th Annual General Meeting scheduled for September 30, 2026 at 11:00 AM IST
- Cut-off/Record date for voting set as September 23, 2026; Book closure from September 24 to September 30, 2026
- E-voting begins on September 26, 2026 (09:00 AM IST) and ends on September 29, 2026 (05:00 PM IST)
- Proposed appointment of Mr. Pulinattu Damodaran Nandakumar as Whole-time Director for 5 years without remuneration
- Proposed appointment of Mr. Ravindra Shivaji Salaskar as Whole-time Director for a 5-year term effective October 9, 2025
Saroja Pharma Industries India Limited held a Board of Directors meeting on September 7, 2026, lasting from 5:00 PM to 6:15 PM IST. The Board approved the Draft Board Report and Management Discussion and Analysis Report for FY 2025-26. Additionally, the Board approved the draft notice for the company's 8th Annual General Meeting and finalized the meeting schedule. No financial results or operational updates were included in this disclosure.
- Board meeting commenced at 05:00 p.m. and concluded at 06:15 p.m. on September 07, 2026
- Approved the Draft Board's Report and annexures for F.Y. 2025-26 under Section 134 of the Companies Act
- Approved the Management Discussion and Analysis Report for F.Y. 2025-26
- Approved Draft Notice for the 8th Annual General Meeting
Saroja Pharma Industries India Limited announced board approvals from its meeting held on August 22, 2026. Mr. Pulinattu Damodaran Nandakumar, who possesses over 35 years of industry experience and is related as a cousin to MD Biju Gopinathan Nair, has been re-designated from Non-Executive Director to Whole-time Director, subject to shareholder approval. Additionally, the company appointed CA Niraj Variava as the Internal Auditor for FY 2026-27. These changes are routine corporate governance and leadership adjustments aimed at supporting expanding operations.
- Re-designation of Mr. Pulinattu Damodaran Nandakumar from Non-Executive Director to Whole-time Director effective August 22, 2026
- Mr. Nandakumar brings over 35 years of experience in the pharmaceutical and chemical sectors
- Appointment of Mr. Niraj Variava, Chartered Accountant, as Internal Auditor for FY 2026-27
- Board meeting commenced at 11:00 AM and concluded at 3:15 PM on August 22, 2026
Financial Performance
Revenue Growth by Segment
The company operates in a single reportable segment: Pharma Chemicals. While absolute revenue was not disclosed, the Net Capital Turnover Ratio increased by 11.77% to 8.25, indicating improved revenue generation efficiency per unit of capital.
Geographic Revenue Split
Not disclosed in available documents, though the company notes significant exposure to global and Indian demand-supply conditions.
Profitability Margins
Net profit ratio was 1.92% for the year ended March 31, 2025, representing a 10.87% decrease from 2.16% in the previous year. Return on Capital Employed (ROCE) fell by 25.45% to 9.50% due to an increase in capital employed.
EBITDA Margin
Not explicitly disclosed; however, the Return on Equity (ROE) declined by 12.17% to 4.14% in FY25 compared to 4.71% in FY24.
Capital Expenditure
The company utilized INR 7.05 Cr (704.88 Lacs) from IPO proceeds to set up a new manufacturing unit to transition from trading to manufacturing. An additional INR 1.75 Cr was used to repay unsecured loans.
Credit Rating & Borrowing
Credit rating not disclosed. The net debt-equity ratio increased by 54.01% to 0.60 in FY25, driven by a likely increase in net borrowings. The Debt Service Coverage Ratio improved by 10.99% to 2.11.
Operational Drivers
Raw Materials
Key products and inputs include Thionyl Chloride, Ethyl Acetate, and Benzyl Chloride. Specific percentage of total cost for each was not disclosed.
Import Sources
Raw materials are primarily sourced from China and India, which are identified as key geographic regions for pharma intermediates.
Capacity Expansion
The company invested INR 7.05 Cr in setting up a manufacturing unit to enhance its production capabilities in pharma chemicals and APIs. Specific MTPA capacity was not disclosed.
Raw Material Costs
Not disclosed as a percentage of revenue, but the company identified 'Input Cost Risk' and raw material price volatility as major concerns that could compress the 1.92% net profit margin.
Manufacturing Efficiency
Capacity utilization was not disclosed; however, the company is focusing on technological advancements to improve operational efficiency.
Strategic Growth
Growth Strategy
Growth is targeted through the operationalization of the new INR 7.05 Cr manufacturing unit, shifting the business model toward higher-margin manufacturing. The company is also focusing on market expansion in emerging regions and innovation in veterinary APIs and pharma intermediates.
Products & Services
Thionyl Chloride, Ethyl Acetate, Benzyl Chloride, Pharma Veterinary APIs, and Pharma Intermediates.
New Products/Services
The company is expanding its portfolio in Pharma Veterinary APIs and Pharma Intermediates, though specific revenue contribution percentages for new launches were not disclosed.
Market Expansion
Targeting emerging markets where healthcare access is expanding rapidly to capitalize on rising demand for pharmaceutical chemicals.
Strategic Alliances
Appointed M/s. H. Maheshwari & Associates as Secretarial Auditors for a five-year term (FY 2025-26 to FY 2029-30) to strengthen regulatory governance.
External Factors
Industry Trends
The pharma chemical and veterinary API sectors are growing due to rising healthcare demands. Trends include a shift toward sustainability, advanced manufacturing technologies, and supply chain resilience.
Competitive Landscape
Faces intense competition from both domestic and international players, as well as disruption from new technologies and biologics in the veterinary segment.
Competitive Moat
The company's moat is based on its specialized focus on pharma chemicals like Thionyl Chloride. However, this is challenged by industry-wide commoditization and rising regulatory barriers to entry in developed markets.
Macro Economic Sensitivity
Highly sensitive to global demand-supply conditions and changes in government tax regimes or economic developments in India and overseas.
Consumer Behavior
Increased healthcare spending and a shift toward generic pharma intermediates in emerging markets are driving demand.
Geopolitical Risks
Geopolitical tensions and trade barriers, particularly involving China and India, pose risks to raw material procurement and cost stability.
Regulatory & Governance
Industry Regulations
Operations are subject to Good Manufacturing Practices (GMP), FDA/EMA quality standards, and environmental safety norms. Compliance is essential to avoid delays and additional costs.
Environmental Compliance
The company faces increasing environmental regulations and stricter standards for chemical manufacturing, requiring compliance with waste management protocols which increase operational costs.
Risk Analysis
Key Uncertainties
Input cost volatility, regulatory scrutiny, and supply chain disruptions are the primary uncertainties, with potential to impact margins by over 10% based on historical net profit fluctuations.
Geographic Concentration Risk
High concentration of raw material sourcing from China and India creates a significant regional risk.
Third Party Dependencies
Dependency on KFIN Technologies Limited for registrar and share transfer services and M/s. Praveen Chandak & Associates for statutory auditing.
Technology Obsolescence Risk
The rise of biologics and new chemical synthesis technologies poses a long-term risk to the company's traditional pharma intermediate products.
Credit & Counterparty Risk
Credit risk is a noted concern; the debtors turnover ratio decreased by 15.62% to 2.51, indicating a potential slowdown in payment collections.
